Go Deep
Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 3,038 | -61.7 | 28.23 | 2.73 | 2,407.51 |
| Oct 2026 | 2,792 | -62.5 | 28.61 | 2.73 | 2,432.55 |
| Oct 2026 | 2,822 | -60.9 | 28.57 | 2.73 | 2,429.10 |
| Oct 2026 | 3,949 | -58.6 | 26.82 | 2.73 | 2,275.05 |
| Oct 2026 | 4,000 | -58.4 | 26.75 | 2.73 | 2,270.85 |
| Oct 2026 | 3,660 | -59.6 | 27.27 | 2.73 | 2,315.42 |
| Oct 2026 | 3,002 | -61.8 | 28.29 | 2.73 | 2,395.77 |
| Oct 2026 | 3,667 | -59.5 | 27.26 | 2.73 | 2,304.08 |
Adaptive Biotechnologies Corporation Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 71,553,000.0 | 70,874,000.0 | 71,681,000.0 | 93,973,000.0 |
| Net Profit | -39,788,000.0 | -20,033,000.0 | -13,579,000.0 | 9,546,000.0 |
| EPS | -0.2 | -0.1 | -0.1 | 0.1 |
Adaptive Biotechnologies Corporation Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 276,976,000.0 | 178,957,000.0 | 170,276,000.0 | 185,308,000.0 |
| Net Profit | -59,499,000.0 | -159,492,000.0 | -225,250,000.0 | -200,191,000.0 |
| EPS | -0.4 | -1.1 | -1.6 | -1.4 |
Adaptive Biotechnologies Corporation Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 512,736,000.0 | 539,376,000.0 | 661,134,000.0 | 856,617,000.0 | — |
| Total Liabilities | 287,735,000.0 | 336,891,000.0 | 352,856,000.0 | 392,519,000.0 | — |
| Total Equity | 218,793,000.0 | 202,709,000.0 | 308,399,000.0 | 464,165,000.0 | — |
Owes vs Owns
Adaptive Biotechnologies Corporation owed $0.76 for every $1 it owned in Jun 2026, up from $0.46 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.76× | 0.56× | 0.62× | 0.53× | 0.46× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Adaptive Biotechnologies Corporation Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 44.3%Receivables 9.8%Inventory 1.9%Fixed assets (tangible) 14.6%Intangible assets 23.5%Long-term investments 2.6%Other assets 3.3%
How it's funded — Dec 2025
Short-term debt 1.7%Long-term debt 13.7%Payables 1.3%Other liabilities 39.4%Shareholders' equity 43.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 227.0 | 222.3 | 346.4 | 498.2 |
| Receivables | 50.4 | 41.7 | 38.0 | 40.1 |
| Inventory | 9.8 | 8.4 | 14.4 | 14.5 |
| Fixed assets (tangible) | 74.7 | 94.4 | 120.3 | 164.2 |
| Intangible assets | 120.7 | 122.4 | 124.1 | 125.8 |
| Long-term investments | 13.2 | 33.7 | 0.0 | 0.0 |
| Other assets | 16.9 | 16.5 | 17.9 | 13.9 |
| Liabilities & equity | ||||
| Short-term debt | 8.9 | 10.2 | 9.4 | 9.2 |
| Long-term debt | 70.2 | 79.1 | 89.4 | 98.8 |
| Payables | 6.5 | 7.3 | 7.7 | 8.1 |
| Other liabilities | 202.1 | 240.2 | 246.4 | 276.4 |
| Shareholders' equity | 225.0 | 202.5 | 308.3 | 464.1 |
| Net tangible assets | 98.1 | 80.3 | 184.3 | 338.4 |
Adaptive Biotechnologies Corporation Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -45,986,000.0 | -95,212,000.0 | -156,324,000.0 | -183,945,000.0 | — |
| Investing Activities | 37,950,000.0 | 77,792,000.0 | 129,647,000.0 | 2,905,000.0 | — |
| Financing Activities | 30,403,000.0 | 241,000.0 | 2,245,000.0 | 132,265,000.0 | — |